Stock Report

All about this stock under one free report Last Updated: 01-Sep-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

BioLineRx - ADR Key Ratios

Stock Card factsheet share-fund-plan-icon

$2.80

up-down-arrow $0.20 (7.69%)

As on 31-Aug-2026 16:11EDT

Market cap

info icon

$11 Mln

Revenue (TTM)

info icon

$1 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

0.7

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 144.35 87.06 -93.72 -- --
EBIT -18.79 -142.15 -267.28 19.55 11.61
Net Profit -14.37 -131.09 -132.63 20.61 12.03
EPS -81.76 -122.67 -26.17 24.10 14.50
Book Value -- -- -37.98 -52.66 -39.66
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-25Dec-24
EBIT-Margin info -427.28-427.28-615.96-63.22-0.51
Net Margin info -----633.66----
Return on equity info -88.61-73.57-43.66-7.48-69.11
Return on Capital info -58.85-53.22---4.17-34.59
Return on Assets info -35.77-36.20-16.17-2.97-17.93
Debt to Equity (x) info ----0.200.561.12

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BioLineRx - ADR
--
-4.17
-34.59
-137.79
-36.72
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

-43.66

Lower than Peers by 17.35

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BioLineRx - ADR
-43.66
-7.48
-69.11
-189.23
-41.96
Peer Median
-26.31
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-16.17

Lower than Peers by 3.21

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BioLineRx - ADR
-16.17
-2.97
-17.93
-86.40
-31.63
Peer Median
-12.96
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

-615.96

Lower than Peers by 556.26

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BioLineRx - ADR
-615.96
-63.22
-0.51
-1,218.13
--
Peer Median
-59.70
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

-633.66

Lower than Peers by 562.60

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BioLineRx - ADR
-633.66
-99.58
-31.86
-1,262.79
--
Peer Median
-71.06
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

0.00

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BioLineRx - ADR
0.00
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

-93.72

Lower than Peers by 114.27

Year on year growth in net sales

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BioLineRx - ADR
-93.72
-0.96
5.03
--
--
Peer Median
20.56
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

-267.28

Lower than Peers by 282.48

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BioLineRx - ADR
-267.28
-411.51
99.75
-156.53
12.57
Peer Median
15.20
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

-132.63

Lower than Peers by 140.49

Year on year growth in profit after tax

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BioLineRx - ADR
-132.63
87.16
84.79
-142.93
7.77
Peer Median
7.86
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

-26.17

Lower than Peers by 56.62

Year on year growth in earnings per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BioLineRx - ADR
-26.17
0.94
0.86
-0.74
0.21
Peer Median
30.45
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

-64.01

Lower than Peers by 65.26

Year on year growth in book value per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BioLineRx - ADR
-64.01
--
--
--
--
Peer Median
1.25
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

0.20

--

Total debt / Net worth

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BioLineRx - ADR
0.20
0.56
1.12
0.88
0.24
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

0.28

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BioLineRx - ADR
0.28
0.26
0.37
0.28
0.04
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

1.58

Lower than Peers by 1.90

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BioLineRx - ADR
1.58
1.95
1.76
1.10
4.87
Peer Median
3.48
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

1.43

Lower than Peers by 1.86

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BioLineRx - ADR
1.43
1.78
1.56
1.06
4.85
Peer Median
3.29
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

-7.77

Lower than Peers by 6.26

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BioLineRx - ADR
-7.77
-0.58
-0.02
-26.96
-10.56
Peer Median
-1.51
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

134.76

Higher than Peers by 110.43

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BioLineRx - ADR
134.76
38.34
13.35
14.75
--
Peer Median
24.33
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.03

Lower than Peers by 0.20

Sales / Average Total Assets

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BioLineRx - ADR
0.03
0.03
0.56
0.07
--
Peer Median
0.23
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BioLineRx - ADR
--
663.18
28.85
54.37
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BioLineRx - ADR
--
1,273.60
100.51
106.35
90.42
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BioLineRx - ADR
--
2,183.86
324.36
882.21
3,499.75
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BioLineRx - ADR
--
-247.09
-195.01
-721.49
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

--

--

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BioLineRx - ADR
--
-10.18
-0.05
-0.05
-0.03
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

0.72

Lower than Peers by 4.24

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BioLineRx - ADR
0.72
0.66
0.03
0.21
0.01
Peer Median
4.96
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BioLineRx - ADR
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

1.11

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BioLineRx - ADR
1.11
-5.91
-1.05
0.50
1.72
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

11

Lower than Peers by 72

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BioLineRx - ADR
11
--
--
--
--
Peer Median
83
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...